EXOZ — eXoZymes Income Statement
0.000.00%
Last trade - 00:00- $120.27m
- $115.29m
Annual income statement for eXoZymes, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | ||||
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 1.21 | 1.33 | 1.8 | 5.93 |
| Operating Profit | -1.21 | -1.33 | -1.8 | -5.93 |
| Total Net Non Operating Interest Income / Expense | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -1.21 | -1.33 | -2 | -5.86 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -1.21 | -1.4 | -2.04 | -5.86 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -1.21 | -1.4 | -2.04 | -5.86 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -1.21 | -1.4 | -2.04 | -5.86 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.159 | -0.172 | -0.251 | -0.893 |
| Dividends per Share |